Two case reports of inverse psoriasis treated with cold atmospheric plasma
Lei Zheng,Jing Gao,Yajing Cao,Xingyu Yang,Na Wang,Cheng Cheng,Chunjun Yang
DOI: https://doi.org/10.1111/dth.14257
2020-08-31
Dermatologic Therapy
Abstract:Dear Editor, Inverse psoriasis is generally recognized as a rare form of psoriasis vulgaris that presents as well-demarcated, erythematous plaques in the flexural skin folds. Current treatments include topical drugs and systemic therapy. However, many side effects were complained. Thus, it is a challenge to explore a nonirritating, high-efficiency and safe therapy to satisfy patients with inverse psoriasis. Plasma is an ionized gas that is considered as a fourth state of nature, consisting of ions, electrons, atoms, radicals, photons and other active species. It can be generated by adding energy to a gas. Cold atmospheric plasma (CAP) has broad application prospects in clinical therapeutics, because it can contact directly with human body without thermal damage. In our previous study, we had used CAP to treat chronic wounds and achieved positive therapeutic effect. On the basis of the above-mentioned findings, we attempted to use CAP to treat inverse psoriasis and assessed its effects. The first case was a 26-year-old woman with a 3-month history of inverse psoriasis, presented with pruritic, erythematous and scaly plaques in the axillae, groin, buttocks and inframammary region. She received topical corticosteroids, vitamin D analogs and oral acitretin (20 mg/d, 2 months), with no remarkable clinical response. Given the poor response, we began CAP treatment two to three times per week without drug therapy after signing informed consent. The CAP device we used was a dielectric barrier discharges generation with four copper needles used as high-voltage electrode designed by the Institute of Plasma Physics Chinese Academy of Sciences (voltage 10 KV, power 50 mW, current 5 mA, treatment temperature less than 30 C). Before treatment, the operator kept one hand on the patient's skin as the ground electrode. Plasma was generated when the device was held at 1 cm distance to the skin surface (Figure 1). Each lesion was treated with 10 minutes except buttocks, which were exposed for 20 minutes. The patient finished the treatment through a total of five plasma treatments and the lesions cleared up almost entirely, leaving brown-red patches (Figure 2). No sign of recurrence had been observed in the following 6 weeks. The second case was a 38-year-old female who had been treated with topical treatment for a 4-year history of scalp psoriasis. The lesions extended to axillae and groin for the last month. Physical examination revealed well-demarcated, erythematous plaques with rare scales in the axillae and groin, and milder scaly plaques in the scalp. After signing informed consent, CAP was performed every 3 days. The duration of treatment was 5 minutes per lesion. After a total of eight treatments, not only did the symptom of pruritus relief obviously, but also a distinct clearance of lesions was observed (Figure 3). No adverse reactions and recurrence were recorded during the treatment and 1-month follow-up. Although the principles of CAP in inverse psoriasis require further study, using CAP as a therapy for inverse psoriasis was based on four considerations: first, plasma inhibited keratinocyte hyperproliferation and induced apoptosis by increasing the levels of reactive oxygen species. Second, it has been shown that CAP could inhibit Th17 cell differentiation and induce programmed cell death ligand 1 (PD-L1) expression that could suppress T cell activation. Third, CAP also played a role in the inhibition of inflammatory cytokine expression, including tumor necrosis factor-α, interleukin (IL)-12, IL-17 and IL22. Fourth, the warm and moist environment of skin regions and long-term use of corticosteroid ointment can increase the risk of secondary infections; CAP has an excellent ability in inhibiting
Medicine